[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336969-105":59,"doc-detail-336969-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tp53-mutations-in-myeloid-neoplasms-implications-for-accurate-laboratory-detection-diagnosis-and-treatment","TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment","","Genetic alterations affecting p53 tumor suppressor function have been widely studied in myeloid neoplasms, with clear consequences for disease progression, therapeutic response, and patient outcomes. Accurate identification and characterization of TP53 mutations are central to subclassifying these disorders and supporting treatment decisions. This review explains the complex TP53 alteration landscape, surveys current laboratory testing methods, and emphasizes the need for robust clinical protocols. It also reviews treatment implications and clinical trial options for precision oncology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tp53-mutations-in-myeloid-neoplasms-implications-for-accurate-laboratory-detection-diagnosis-and-treatment/336969/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tp53-mutations-in-myeloid-neoplasms-implications-for-accurate-laboratory-detection-diagnosis-and-treatment/336969.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are TP53 mutations important in myeloid neoplasms?","Question",{"text":112,"@type":113},"They affect p53 tumor suppressor function, influencing disease progression and patient outcomes. TP53 mutation identification also helps subclassify myeloid neoplasms and guide treatment decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What laboratory challenge is highlighted for TP53 testing?",{"text":117,"@type":113},"TP53 alterations can be complex, making it difficult to detect all relevant changes in clinical samples using a single test or simple protocol. The review stresses establishing robust testing protocols to ensure accurate, reliable results.",{"name":119,"@type":110,"acceptedAnswer":120},"How do updated classification systems relate to TP53?",{"text":121,"@type":113},"The WHO-HEAM 5th edition and the International Consensus Classification incorporate more molecular genetic alterations. TP53 mutations are promoted as a defining criterion, and detecting multihit TP53 mutations is required for subclassification of MDS and AML.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336969,1790870275,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","OVERVIEW  \nTP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment  \nLinsheng Zhang, MD, PhD,1, BroojAbro, MD,1 Andrew Campbell, PhD,2 Yi Ding, MD, PhD2  \n1Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, US; 2Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, US. Corresponding author: Yi Ding; [yding1@geisinger.edu](yding1@geisinger.edu)  \nKey words: myelodysplastic syndrome; acute myeloid leukemia; myeloid neoplasm; TP53; genetic techniques; sequence analysis  \nAbbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic neoplasms/syndrome; MPN, myeloproliferative neoplasm; IPSS-M, Molecular International Prognostic Scoring System; WHO-HEAM5, World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 5th Edition; ICC, International Consensus Classification; SNVs, single nucleotide variants; MNVs, multiple nucleotide variants; indels, insertions and deletions; SVs, structural variants; 17p, whole arm; IHC, immunohistochemical; NGS, nextgeneration sequencing; VAF, variant allele frequency; MRD, measurable residual disease; AEL, acute erythroid leukemia; WHO-4RE, World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, Revised 4th Edition; LFS, Li-Fraumeni syndrome; WT, wild type; GOF, gain-of-function; tMNs, therapy-related myeloid neoplasms; tMDS, therapy-related MDS; HSCT, hematopoietic stem cell transplantation; PARPi, poly (ADP-ribose) polymerase inhibitor CNV, copy number variation/alteration; HSPCs, hematopoietic stem/ progenitor cells; CHIP, clonal hematopoiesis of indeterminate potential; LOH, loss of heterozygosity; UPD, uniparental disomy; OS, overall survival; EAp53, evolutionary action score; RFS, relative fitness score; OGM, optical genome mapping; WES, whole exome sequencing, WGS, whole genome sequencing; PCR, polymerase chain reaction; VUS, variants of unknown significance; FFPE, formalin-fixed paraffin-embedded; NCCN, National Comprehensive Cancer Network; HMAs, hypomethylation agents; alloHSCT allogeneic HSCT; CIBMTR, Center for International Blood and Marrow Transplant ResearchFISH fluorescence in situ hybridizationAACR American Association for Cancer Research  \nLaboratory Medicine 2024;55:686-699; [https://doi.org/10.1093/labmed/lmae048](https://doi.org/10.1093/labmed/lmae048)  \nABSTRACT  \nGenetic alterations that affect the function of p53 tumor suppressor have been extensively investigated in myeloid neoplasms, revealing their significant impact on disease progression, treatment response, and patient outcomes. The identification and characterization of TP53 mutations play pivotal roles in subclassifying myeloid neoplasms and guiding treatment decisions. Starting with the presentation of a typical case, this review highlights the complicated nature of genetic alterations involving TP53 and provides a comprehensive analysis  \nof TP53 mutations and other alterations in myeloid neoplasms. Currently available methods used in clinical laboratories to identify TP53 mutations are discussed, focusing on the importance of establishing a robust testing protocol within clinical laboratories to ensure the delivery of accurate and reliable results. The treatment implications of TP53 mutations in myeloid neoplasms and clinical trial options are reviewed. Ultimately, we hope that this review provides valuable insights into the patterns of TP53 alterations in myeloid neoplasms and offers guidance to establish practical laboratory testing protocols to support the best practices of precision oncology.  \nIntroduction  \nMyeloid neoplasms are a group of hematopoietic disorders originating from the abnormal clonal proliferation of stem or myeloid progenitor cells, resulting in blood cell changes with or without solid organ infiltration by neoplastic myeloid cells and associated clinical presentations. Depending on the clinical onset, ","cbCaioWvLati4DXe","https://ap.wps.com/l/cbCaioWvLati4DXe","pdf",5117995,14,"English","# Overview\n## Abstract\n## Introduction\n## Laboratory methods and testing protocol\n## Treatment implications and clinical trial options","[{\"question\":\"Why are TP53 mutations important in myeloid neoplasms?\",\"answer\":\"They affect p53 tumor suppressor function, influencing disease progression and patient outcomes. TP53 mutation identification also helps subclassify myeloid neoplasms and guide treatment decisions.\"},{\"question\":\"What laboratory challenge is highlighted for TP53 testing?\",\"answer\":\"TP53 alterations can be complex, making it difficult to detect all relevant changes in clinical samples using a single test or simple protocol. The review stresses establishing robust testing protocols to ensure accurate, reliable results.\"},{\"question\":\"How do updated classification systems relate to TP53?\",\"answer\":\"The WHO-HEAM 5th edition and the International Consensus Classification incorporate more molecular genetic alterations. TP53 mutations are promoted as a defining criterion, and detecting multihit TP53 mutations is required for subclassification of MDS and AML.\"}]","TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment | PDF",1790017249,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9b06f36a87c817dac2323d90b81ca56.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da90457c703d1f2c508492021b05fabf.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41bbafe8d364d5f2a488dc61c857c857.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/038ea56c55f9a64151bac640b415c8df.webp",980,1306]